Company intelligence / Profile preview
Indalo Therapeutics
St. Louis, Missouri, USAindalotherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
IDL‑2965 has completed a Phase I clinical trial evaluating safety, tolerability, and pharmacokinetics in healthy subjects and patients with idiopathic pulmonary fibrosis. The study aimed to provide data supporting further development in fibrotic indications such as NASH and IPF. No detailed efficacy results are publicly available yet.
- Therapeutic areas
- GastroenterologyPulmonology
- Modalities
- Small molecules (specifically integrin antagonists)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharma partnerships disclosed.
Beyond the preview
Go deeper on Indalo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Indalo Therapeutics.